Protalix BioTherapeutics (PLX) Operating Income (2010 - 2026)

Protalix BioTherapeutics' Operating Income history runs 17 years deep, the most recent figure standing at $21.1 million for Q1 2026.

• In Q1 2026, Operating Income rose 610.16% year-over-year to $21.1 million; the TTM figure through Mar 2026 stood at $24.1 million (up 421.02% YoY), while the FY2025 annual figure was -$1.2 million, down 130.07% from the prior year.
• Operating Income was $21.1 million for Q1 2026 at Protalix BioTherapeutics, up from -$336000.0 in the prior quarter.
• In the past five years, Operating Income ranged from a high of $21.1 million in Q1 2026 to a low of -$5.6 million in Q4 2023.
• Historically, Operating Income has averaged $1.8 million across 5 years, with a median of -$1.9 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Operating Income tumbled 174.91% in 2023, then jumped 610.16% in 2026.
• A 5-year view of Operating Income shows it stood at $7.5 million in 2022, then sank by 174.91% to -$5.6 million in 2023, then jumped by 228.39% to $7.2 million in 2024, then slumped by 104.66% to -$336000.0 in 2025, then soared by 6393.45% to $21.1 million in 2026.
• The last three Operating Income figures came in at $21.1 million (Q1 2026), -$336000.0 (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.